Enhancing monitoring of FTD
There are no FDA approved therapies for FTD, but clinical trials are underway. FTD is a group of disorders characterised by changes to behaviour, language, motor speech, and activities of daily living.
Redenlab scientists are leading the field of FTD communication research. They partner with global key opinion leaders across natural history studies and treatment trials. Communication is adversely impacted across all FTD phenotypes making it an ideal marker of quality of life and overall disease function.
Differentiate FTD from other diseases
The diagnostic journey for people with FTD can be long. The FTD disease profile can be confused with other diseases such as Alzheimer’s and other forms of dementia, with almost 40% of patients initially misdiagnosed. The unique speech and language phenotypes within the FTD spectrum means communication can be used to assist in differential diagnosis.
Manage your FTD trials with ease
Redenlab offers a suite of management tools to assess, validate and analyse FTD studies across more than 100 sites globally. Redenlab’s objective markers of speech and language are being used to monitor changes in patient performance, enhancing therapeutic development decisions in your next clinical trial.
Leading analytics among leading academics
Redenlab partners with the world leading clinician researchers in FTD. Partnerships include:
- Memory and Aging Center – UCSF, USA
- UCL Queen Square Institute of Neurology, UK
- Eastern Cognitive Disorders Clinic, Melbourne, Australia
- The University of Melbourne, Australia
- University of Texas in Austin, USA
Use cases for communication monitoring in FTD
Post marketing
CNS health
Communication related quality of life
Treatment efficacy
Latest news and updates
- Posted on 28 January, 2025
- Posted on 19 November, 2024